EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides



Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides



Journal of Infectious Diseases 180(2): 369-376



Atovaquone suspensions (750 mg and 1500 mg once daily) were compared with aerosolized pentamidine (300 mg once monthly) for the prevention of P. carinii pneumonia (PCP) in 549 HIV-positive subjects from Canada and the USA, who were intolerant to trimethoprim or sulfonamides (or both). Median time using the assigned therapy was 6.6 months, and the median follow-up was 11.3 months.

(PDF emailed within 0-6 h: $19.90)

Accession: 003048735

Download citation: RISBibTeXText

PMID: 10395851

DOI: 10.1086/314893



Related references

Aerosolized pentamidine for the prevention of pneumocystis carinii pneumonia in cancer patients intolerant or allergic to trimethoprim sulfamethoxazole. Pediatric Research 29(4 PART 2): 146A, 1991

Aerosolized pentamidine for the prevention of Pneumocystis carinii pneumonia in children with cancer intolerant or allergic to trimethoprim/sulfamethoxazole. Journal of Clinical Oncology 12(2): 258-261, 1994

Aerosolized pentamidine ap for the prevention of pneumocystis carinii pneumonia pcp in children with cancer ca intolerant or allergic to trimethoprim sulfamethoxazole tmp smx. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 32: 296, 1992

Prevention of pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus infected patients a clinical approach comparing aerosolized pentamidine and pyrimethamine sulfadoxine. Clinical Investigator 70(6): 508-512, 1992

Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. New England Journal of Medicine 339(26): 1889-1895, Dec 24, 1998

A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. AIDS Forschung 8(4): 177-178, 1993

Intrapulmonary and systemic pharmacokinetics of aerosolized pentamidine used for prophylaxis of pneumocystis carinii pneumonia in patients infected with the human immunodeficiency virus. Journal of Clinical Pharmacology 35(12): 1166-1173, 1995

A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. New England Journal of Medicine 327(26): 1836-1841, 1992

Effect of aerosolized pentamidine prophylaxis on the diagnosis of Pneumocystis carinii pneumonia by induced sputum examination in patients infected with the human immunodeficiency virus. American Review of Respiratory Disease 144(4): 760-764, 1991

Treatment of Pneumocystis carinii pneumonia (PCP) with trimethoprim-sulfamethoxazole and pentamidine in human immunodeficiency virus (HIV) infected patients--a case study and review of literature. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 62(6): 551-556, 1988

Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clinical Infectious Diseases 20(3): 531-541, 1995

Intramuscular pentamidine for the prevention of Pneumocystis carinii pneumonia in patients infected with human immunodeficiency virus. Clinical Infectious Diseases 16(1): 22-25, 1993

Intramuscular pentamidine for the prevention of Pneumocystis carinii pneumonia in patients infected with human immunodeficiency virus. Clinical Infectious Diseases 16(1): 22-25, 1992